Cystatin C as an antagonist of TGF-β and methods related thereto
View Patent ↗Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy and invasion and other TGF-β-mediated fibrotic or proliferative conditions and diseases.
1. A method to inhibit TGF-β-mediated tumor malignancy or invasion, comprising administering to a tumor cell a Cystatin C protein consisting of:
a fragment of SEQ ID NO:2, wherein the fragment differs from SEQ ID NO:2 by a deletion of at least 30 amino acids from the N-terminus of SEQ ID NO:2 and comprises at least the last 45 C-terminal amino acids of SEQ ID NO:2, wherein the fragment inhibits TGF-β signaling;
wherein the administration of the Cystatin C protein inhibits TGF-β-mediated tumor malignancy or invasion.
2. The method of claim 1 , wherein the Cystatin C protein further inhibits the protease activity of extracellular cathepsin B.
3. The method of claim 1 , wherein the Cystatin C protein further inhibits cathepsin B-mediated activation of TGF-β in the cell or tissue or in the microenvironment of the cell or tissue.
4. A method to inhibit TGF-β-mediated tumor malignancy or invasion, comprising administering to a tumor cell a Cystatin C protein consisting of an amino acid sequence that is less than 98% identical to the amino acid sequence of SEQ ID NO:2 and at least 90% identical to the amino acid sequence of SEQ ID NO:2, wherein the protein inhibits TGF-β signaling, wherein the amino acid sequence of the Cystatin C protein differs from SEQ ID NO:2 by a disruption of SEQ ID NO:2 sufficient to reduce or abolish the biological activity of the conserved cysteine proteinase inhibitor motif of Cystatin C;
wherein the administration of the Cystatin C protein inhibits TGF-β-mediated tumor malignancy or invasion.
5. The method of claim 4 , wherein the conserved cysteine proteinase inhibitor motif is located between about position 80 and about position 93 of SEQ ID NO:2.
6. A method to inhibit TGF-β-mediated tumor malignancy or invasion, comprising administering to a tumor cell a Cystatin C protein consisting of an amino acid sequence that is less than 98% identical to the amino acid sequence of SEQ ID NO:2 and at least 90% identical to the amino acid sequence of SEQ ID NO:2, wherein the protein inhibits TGF-β signaling, wherein the amino acid sequence of the Cystatin C protein comprises a deletion from about position 80 to about position 93 of SEQ ID NO:2;
wherein the administration of the Cystatin C protein inhibits TGF-β-mediated tumor malignancy or invasion.
7. The method of claim 1 , wherein the fragment comprises at least about 100 amino acids of the C-terminal portion of SEQ ID NO:2.
8. The method of claim 1 , wherein the fragment comprises at least about 75 amino acids of the C-terminal portion of SEQ ID NO:2.
9. The method of claim 1 , wherein the fragment of comprises at least about 55 amino acids of the C-terminal portion of SEQ ID NO:2.
10. The method of claim 1 , wherein the fragment differs from SEQ ID NO:2 by a deletion of at least about 40 amino acids from the N-terminus of SEQ ID NO:2.
11. The method of claim 1 , wherein the fragment differs from SEQ ID NO:2 by a deletion of at least about 60 amino acids from the N-terminus of SEQ ID NO:2.
12. The method of claim 1 , wherein the fragment differs from SEQ ID NO:2 by a deletion of 50 amino acids from the N-terminus of SEQ ID NO:2.